UH Seidman Cancer Center Leadership

June 8, 2017

To:       University Hospitals Physicians and Leaders

From:   Daniel I. Simon, MD
             President, UH Cleveland Medical Center

             Nathan Levitan, MD
             President, UH Seidman Cancer Center

Date:    June 7, 2017

University Hospitals Seidman Cancer Center has an exceptional opportunity to further enhance its leading role in cancer care, teaching and research as the Case Comprehensive Cancer Center transitions into a new grant phase.

We are pleased to announce that John J. Letterio, MD, will become the interim Director of UH Seidman Cancer Center as Stan Gerson, MD, transitions his role on July 1. Dr. Letterio will serve in this important position while a national search is conducted. John Letterio, MD

As interim Director, Dr. Letterio will provide leadership for the academic components of UH Seidman Cancer Center physician activities, while engaging in faculty physician recruitment and retention. He will also contribute to the development, implementation and oversight of our cancer center strategic plans, clinical programs and operational priorities – including programmatic integration among adult, pediatric and adolescent cancer services. Additionally, he will oversee the UH Seidman Cancer Center Clinical Trials Unit.

Dr. Letterio was recruited from the National Institutes of Health in 2005 to lead the Division of Pediatric Hematology/Oncology at UH Rainbow Babies & Children’s Hospital, and he has served as Director of the Angie Fowler Adolescent & Young Adult Cancer Institute since it was established 2011. He is a Professor of Pediatrics and holds the Jane and Lee Seidman Chair in Pediatric Cancer Innovation.

Dr. Letterio’s research has defined important roles for the transforming growth factors-β in immunity and cancer, and his efforts have recently led to the very first clinical trial with an inhibitor of this pathway in patients with multiple myeloma, soon to open at UH. Dr. Letterio was named a 2017 Harrington Scholar-Innovator by the Harrington Discovery Institute at University Hospitals, recognizing the development of a novel inhibitor of Cdk5, an emerging therapeutic target in cancer and other diseases, including Alzheimer’s disease and other forms of neurodegenerative disease.

We look forward to working with Dr. Letterio as he begins his new responsibilities. We are confident his leadership will advance our clinical, educational and research objectives at UH Seidman Cancer Center. Please join us in congratulating and supporting him.

Important Links & Numbers

Refer A Patient

Call Direct 866-UH4-CARE (866-844-2273)
or 800-552-8338

Transfer Referral Line

216-844-1111 or

UH Physician Portal

Find a UH Facility

Contact a UH Physician Liaison Team Member Direct
(216) 286-9024